SUNNYVALE, Calif., Feb. 12 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a developmental stage biopharmaceutical company with four drug candidates in clinical testing and several late stage preclinical programs, announced today the appointment of a new management team and a new board member.
Robert W. Duggan, our Chairman of the Board, has been appointed CEO of the
company after acting as interim CEO for the past five months. Mr. Duggan is
considered one of the founders of robotic surgery. He served as Chairman of
the Board of Directors of Computer Motion, Inc., a computerized surgical
systems company, from 1990 to 2003 and Chief Executive Officer from 1997.
Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. Mr. Duggan
currently serves as a director of Intuitive Surgical, Inc. Mr. Duggan has been
a private venture investor for more than 30 years and has participated as a
director of, investor in and advisor to numerous small and large businesses in
the medical equipment, computer local and wide area network, PC hardware and
software distribution, digital encryption, consumer retail goods and outdoor
media communication industries. He received the Congressman's Medal of Merit
and in 2000 he was named a Knight of the Legion of Honor by President Jacques
Chirac. He is a member of the
Glenn C. Rice, Ph.D has been appointed President and COO. Dr. Rice has
over 25 years of oncology drug development experience in the biopharmaceutical
industry including research, preclinical and clinical trials as well as
extensive experience in licensing, partnerships and M&A. He was the CEO and
Founder of Bridge Laboratories (a la
|SOURCE Pharmacyclics, Inc.|
Copyright©2009 PR Newswire.
All rights reserved